Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case series.

Frontiers in oncology·2026
Same author

Pre-diagnostic route reported by patients with sarcoma from the Netherlands, the UK, Australia and New Zealand: early detection challenges for general practitioners - an international observational cohort study.

BMJ open·2026
Same author

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Optimal clinical management of tenosynovial giant cell tumours: a UK perspective.

Bone & joint open·2026
Same author

Analysis of Clinical Benefit Using DNG64-<i>CAR-V</i> Chimeric Tumor Targeted Amphotropic RNA Vector in <i>CCNG1</i> Expressing Cancers.

Anticancer research·2026
Same journal

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.

Future oncology (London, England)·2026
Same journal

Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.

Future oncology (London, England)·2026
Same journal

Disparities in mortality among HER2-positive breast cancer patients treated with trastuzumab in Chile (2015-2024): real-world evidence from 4,920 cases.

Future oncology (London, England)·2026
Same journal

VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma.

Future oncology (London, England)·2026
Same journal

Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy.

Future oncology (London, England)·2026
Same journal

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.

Future oncology (London, England)·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

How I treat soft tissue sarcomas.

Javier Pozas1,2, Niveditha Vasagiri3, Ioanna Nixon4

  • 1Medical Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UK.

Future Oncology (London, England)
|May 21, 2026
PubMed
Summary
This summary is machine-generated.

Soft tissue sarcomas require multidisciplinary care. Histology-specific trials are crucial for developing targeted therapies and improving outcomes for these rare mesenchymal malignancies.

Keywords:
Soft tissue sarcomaschemotherapymultidisciplinary managementradiotherapysurgery

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Related Experiment Videos

Last Updated: May 22, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Soft tissue sarcomas are rare mesenchymal malignancies with diverse behaviors.
  • Current treatments include surgery, radiotherapy, and chemotherapy, but challenges remain.

Purpose of the Study:

  • To provide a comprehensive review of current soft tissue sarcoma treatment strategies.
  • To emphasize multidisciplinary management and histology-specific approaches.

Main Methods:

  • Literature review of current treatment modalities for soft tissue sarcomas.
  • Analysis of established and emerging therapeutic strategies.
  • Emphasis on multidisciplinary care and personalized medicine.

Main Results:

  • Surgery is standard for localized disease; perioperative radiotherapy is used for high-risk tumors.
  • Anthracycline chemotherapy is first-line for metastatic disease, but resistance is common.
  • Immunotherapies and targeted therapies show promise for specific subtypes based on molecular profiling.

Conclusions:

  • Multidisciplinary management is essential for soft tissue sarcomas.
  • Developing histology-specific clinical trials is critical for advancing treatment and improving patient outcomes.
  • Targeted therapies based on molecular profiling offer new hope for rare malignancies.